New combo therapy for rectal cancer moves to safety testing
NCT ID NCT04104139
First seen Oct 31, 2025 · Last updated Apr 30, 2026 · Updated 32 times
Summary
This early-stage study tests the safety of combining the chemotherapy drug TAS-102 with radiation therapy for people with stage II or III rectal cancer that hasn't been treated yet. About 19 participants will receive the drug along with radiation before surgery to find the safest dose and watch for side effects. The goal is to see if this combination can be given without causing too many severe problems.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RECTAL ADENOCARCINOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
OHSU Knight Cancer Institute
Portland, Oregon, 97239, United States
Conditions
Explore the condition pages connected to this study.